Lipoprotein (a) is a low-density lipoprotein that transports cholesterol in the blood. The lipoprotein (a) test — or Lp(a) test — determines the level of this lipoprotein in the blood, and its results ...

A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A.

Youth with obesity have an altered high-density lipoprotein (HDL) subspecies profile characterized by depletion of large apoE-rich HDL particles and an enrichment of small HDL particles. The goal of ...

Thirty-year outcomes among participants in the Women's Health Study showed a stepwise increase in major cardiovascular events associated with increasing lipoprotein(a) levels starting around 30-60 ...

Please provide your email address to receive an email when new articles are posted on . The FDA cleared a new lipoprotein assay designed to measure lipoprotein(a) in nmol/L. Measuring nmol/L rather ...

Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...

A new study shows that a different metric, a measure of HDL function called cholesterol efflux capacity, is more closely associated with protection against heart disease than HDL cholesterol levels ...

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular events in initially healthy women. Elevated plasma lipoprotein(a) is a ...

We are paying more attention to Lipoprotein (a), our next major marker in our ability to care for the heart Dr. Gajinder Kumar Goyal, Program Clinical Director - Cardiology, Marengo Asia Hospitals ...

HDL is short for high-density lipoprotein. Each bit of HDL cholesterol is a microscopic blob that consists of a rim of lipoprotein surrounding a cholesterol center. The HDL cholesterol particle is ...

Adults with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event who received the oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor enlicitide ...